|1.||Jabbour, Henry N: 10 articles (01/2011 - 02/2004)|
|2.||Sales, Kurt J: 9 articles (01/2010 - 02/2004)|
|3.||Anderson, Richard A: 7 articles (01/2011 - 02/2004)|
|4.||Williams, Alistair R W: 6 articles (01/2010 - 02/2004)|
|5.||Narumiya, Shuh: 4 articles (01/2013 - 01/2009)|
|6.||Zhang, Yun: 3 articles (12/2015 - 06/2012)|
|7.||Zhong, Ming: 3 articles (12/2015 - 06/2012)|
|8.||Ti, Yun: 3 articles (12/2015 - 06/2012)|
|9.||Zhang, Wei: 3 articles (12/2015 - 06/2012)|
|10.||Doré, Sylvain: 3 articles (01/2013 - 01/2009)|
02/01/1997 - "Transgenic studies involving FP receptor knock-out animals may provide future insight into the role of this receptor in glaucoma. "
03/01/2011 - "5. Monkey experimental high IOP glaucoma models revealed that in the glaucomatous optic nerve head vaso-constrictive reactions to an alpha-1 agonist was abolished, while vasodilative reaction to a prostaglandin FP receptor agonist was retained. "
08/01/2008 - "Despite the prominent role FP-receptor agonists play in the treatment of glaucoma, our understanding of how these agents lower IOP remains incomplete. "
01/01/2007 - "A combined method of denaturing High Performance Liquid Chromatography (dHPLC) and sequencing was applied to detection of the PGF2alpha receptor gene variant among the 76 Malaysian patients with glaucoma, and a novel single nucleotide polymorphism (SNP), IVS -97A>T, was identified. "
01/01/2007 - "A novel single nucleotide polymorphism, IVS2 -97A>T, in the prostaglandin F2alpha receptor gene was identified among the Malaysian patients with glaucoma."
|2.||Ocular Hypertension (Glaucoma, Suspect)
08/01/2008 - "The topical application of prostaglandin F(2 ) (FP)-receptor agonists has been shown to significantly lower intraocular pressure (IOP) in humans and is now considered the first-line treatment for ocular hypertension. "
10/01/2006 - "AL-12180 is a relatively potent and selective FP-receptor agonist whose isopropyl ester prodrug (AL-12182) lowers IOP by as much as 40% following topical ocular dosing in a laser-induced nonhuman primate model of ocular hypertension."
01/01/2010 - "A new prostanoid FP receptor analog, tafluprost, has been introduced into the medical treatment of glaucoma and ocular hypertension. "
04/01/2014 - "To examine whether intraocular pressure (IOP) reduction by latanoprost correlates with single nucleotide polymorphisms (SNPs) of the prostaglandin F2α (FP) receptor gene in patients with glaucoma and ocular hypertension (OH). "
10/01/2001 - "Travoprost (0.0015% and 0.004%), a highly selective, potent prostaglandin F (FP) receptor agonist, is equal or superior to latanoprost and superior to timolol in lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. "
06/01/2014 - "FP-receptor gene silencing may exert a protective effect on DCM by improving myocardial fibrosis, suggesting a new therapeutic approach for human DCM. "
06/01/2014 - "FP-receptor gene silencing ameliorates myocardial fibrosis and protects from diabetic cardiomyopathy."
06/01/2014 - "FP-receptor gene silencing decreases collagen expression and ameliorates myocardial fibrosis in T2D. "
06/01/2014 - "We established the type 2 diabetes rat model by high-fat diet and low-dose streptozotocin (STZ) and then evaluated its characteristics by metabolite tests, Western blot analysis for FP-receptor expression, histopathologic analyses of cardiomyocyte density and fibrosis area. "
12/01/2009 - "Here we show that loss of prostaglandin F (PGF) receptor (FP) selectively attenuates pulmonary fibrosis while maintaining similar levels of alveolar inflammation and TGF-beta stimulation as compared to wild-type (WT) mice, and that FP deficiency and inhibition of TGF-beta signaling additively decrease fibrosis. "
|5.||Demyelinating Diseases (Demyelinating Disease)
11/01/2014 - "These data suggest that during cuprizone-induced demyelination, PGF2α/FP receptor signaling contributes to glial activation, neuroinflammation, and demyelination, resulting in motor dysfunction. "
11/01/2014 - "To investigate the effects of PGF2α/FP receptor signaling on demyelination, we administrated FP receptor agonist and antagonist to cuprizone-exposed mice, a model of multiple sclerosis. "
11/01/2014 - "Prostaglandin F2α FP receptor inhibitor reduces demyelination and motor dysfunction in a cuprizone-induced multiple sclerosis mouse model."
11/01/2014 - "Administration of the FP receptor antagonist AL-8810 attenuated cuprizone-induced demyelination, glial activation, and TNFα expression in the corpus callosum, and also improved the motor function. "
|5.||prostaglandin F2alpha receptor
|6.||Prostaglandins F (PGF)
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)